Novel nucleic acid structures containing a poly-A tail having a secondary or tertiary structure and their applications

Nucleic acid structures with poly(A) tail secondary or tertiary formations enhance mRNA stability and protein expression by using complementary binding sequences, addressing degradation issues and improving therapeutic efficacy.

JP2026518071APending Publication Date: 2026-06-03SAMSUNG BIOLOGICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
SAMSUNG BIOLOGICS CO LTD
Filing Date
2024-05-24
Publication Date
2026-06-03

AI Technical Summary

Technical Problem

Existing mRNA-based vaccines and gene therapies face challenges in maintaining intracellular stability and protein expression levels due to rapid degradation by ribonucleases, with insufficient focus on optimizing the poly(A) tail at the 3' end of the mRNA structure.

Method used

Development of nucleic acid structures with a coding region for polypeptides or proteins and a poly(A) tail forming secondary or tertiary structures such as stem-loop, bulge stem, or pseudoknot structures using complementary binding sequences to enhance stability and protein expression.

Benefits of technology

The proposed structures significantly improve intracellular stability and protein expression levels by forming stable secondary or tertiary structures, maintaining high efficiency without interference from UTR or CDS sequences.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026518071000001_ABST
    Figure 2026518071000001_ABST
Patent Text Reader

Abstract

The present invention relates to a novel nucleic acid structure with improved stability and protein expression levels, and its applications, and more particularly to a nucleic acid structure comprising a coding region for encoding a polypeptide or protein; and a poly(A) tail having a secondary or tertiary structure; and a pharmaceutical composition for vaccines or gene therapy comprising the nucleic acid structure. In the case of the nucleic acid structure platform according to the present invention, improved stability and protein expression rates are observed in cells without interference with CDS, UTR sequences, etc., and therefore it can be widely and usefully used in the fields of gene therapy and vaccines.
Need to check novelty before this filing date? Find Prior Art